Analysis of outcomes after radical prostatectomy in patients eligible for active surveillance (PRIAS)

被引:52
作者
El Hajj, Albert [1 ]
Ploussard, Guillaume [1 ]
de la Taille, Alexandre [1 ]
Allory, Yves [2 ]
Vordos, Dimitri [1 ]
Hoznek, Andras [1 ]
Abbou, Claude Clement [1 ]
Salomon, Laurent [1 ]
机构
[1] CHU Henri Mondor, APHP, Dept Urol, F-94010 Creteil, France
[2] CHU Henri Mondor, APHP, Dept Pathol, F-94010 Creteil, France
关键词
active surveillance; low risk; prostate cancer; radical prostatectomy; biopsy; CANCER PATIENTS; PATHOLOGICAL OUTCOMES; STRINGENT CRITERIA; EPSTEIN CRITERIA; REPEAT BIOPSY; RISK; MEN; VALIDATION; CANDIDATES; EXPERIENCE;
D O I
10.1111/j.1464-410X.2012.11276.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective To identify the risk of failure of active surveillance (AS) in men who had the Prostate Cancer Research International: Active Surveillance (PRIAS) criteria and had undergone radical prostatectomy (RP), by studying as primary endpoints the risk of unfavourable disease in RP specimens (stage >T2 and/or Gleason score >6) and of biochemical progression after RP. Patients and Methods We assessed 626 patients who had the PRIAS criteria for AS defined as T1c/T2, PSA level of <= 10 ng/mL, PSA density (PSAD) of <0.2 ng/mL per mL, Gleason score of <7, and one or two positive biopsies. All patients underwent immediate RP at our department between January 1991 and December 2010. Multivariate logistic regression was used to test factors correlated with the risk of unfavourable prostate cancer. The risk of progression was tested using multivariate Cox regression models. Biochemical recurrence-free survival (BFS) was established using the Kaplan-Meier method Results Pathological study of RP specimens showed upstaging (>T2) in 129 patients (20.6%), upgrading (Gleason score >6) in 281 (44.9%) and unfavourable disease in 312 patients (50%). There was a statistically non-significant trend for BFS at P = 0.06. Predictors of favourable tumours were age <65 years (P = 0.005), one vs two positive biopsies (P = 0.01) and a biopsy core number >12 (P = 0.005). Preoperative factors predicting disease progression were a PSAD of >0.15 ng/mL(2) (P = 0.008) and biopsy core number of <= 12 (P = 0.017). Conclusions Even with stringent AS criteria, the rate of unfavourable disease remains high. Predictive factors of unfavourable disease and biochemical progression should be considered when including patients in AS protocols.
引用
收藏
页码:53 / 59
页数:7
相关论文
共 30 条
  • [21] The Role of Biopsy Core Number in Selecting Prostate Cancer Patients for Active Surveillance
    Ploussard, Guillaume
    Xylinas, Evanguelos
    Salomon, Laurent
    Allory, Yves
    Vordos, Dimitri
    Hoznek, Andras
    Abbou, Claude-Clement
    de la Taille, Alexandre
    [J]. EUROPEAN UROLOGY, 2009, 56 (06) : 891 - 898
  • [22] Percent tumor involvement and risk of biochemical progression after radical prostatectomy
    Rampersaud, Edward N.
    Sun, Leon
    Moul, Judd W.
    Madden, John
    Freedland, Stephen J.
    [J]. JOURNAL OF UROLOGY, 2008, 180 (02) : 571 - 576
  • [23] Careful Selection and Close Monitoring of Low-Risk Prostate Cancer Patients on Active Surveillance Minimizes the Need for Treatment
    Soloway, Mark S.
    Soloway, Cynthia T.
    Eldefrawy, Ahmed
    Acosta, Kristell
    Kava, Bruce
    Manoharan, Murugesan
    [J]. EUROPEAN UROLOGY, 2010, 58 (06) : 831 - 835
  • [24] Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients
    Suardi, Nazareno
    Gallina, Andrea
    Capitanio, Umberto
    Salonia, Andrea
    Lughezzani, Giovanni
    Freschi, Massimo
    Mottrie, Alexander
    Rigatti, Patrizio
    Montorsi, Francesco
    Briganti, Alberto
    [J]. CANCER, 2012, 118 (04) : 973 - 980
  • [25] Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer
    Suardi, Nazareno
    Briganti, Alberto
    Gallina, Andrea
    Salonia, Andrea
    Karakiewicz, Pierre I.
    Capitanio, Umberto
    Freschi, Massimo
    Cestari, Andrea
    Guazzoni, Giorgio
    Rigatti, Patrizio
    Montorsi, Francesco
    [J]. BJU INTERNATIONAL, 2010, 105 (11) : 1548 - 1552
  • [26] Thaxton CS, 2010, UROLOGY, V75, P414, DOI 10.1016/j.urology.2009.07.1353
  • [27] Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience
    Tosoian, Jeffrey J.
    Trock, Bruce J.
    Landis, Patricia
    Feng, Zhaoyong
    Epstein, Jonathan I.
    Partin, Alan W.
    Walsh, Patrick C.
    Carter, H. Ballentine
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (16) : 2185 - 2190
  • [28] Prospective validation of active surveillance in prostate cancer: The PRIAS study
    van den Bergh, Roderick C. N.
    Roemeling, Stijn
    Roobol, Monique J.
    Roobol, Wouter
    Schroder, Fritz H.
    Bangma, Chris H.
    [J]. EUROPEAN UROLOGY, 2007, 52 (06) : 1560 - 1563
  • [29] Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study
    van den Bergh, Roderick C. N.
    Vasarainen, Hanna
    van der Poel, Henk G.
    Vis-Maters, Jenneke J.
    Rietbergen, John B.
    Pickles, Tom
    Cornel, Erik B.
    Valdagni, Riccardo
    Jaspars, Joris J.
    van der Hoeven, John
    Staerman, Frederic
    Oomens, Eric H. G. M.
    Rannikko, Antti
    Roemeling, Stijn
    Steyerberg, Ewout W.
    Roobol, Monique J.
    Schroder, Fritz H.
    Bangma, Chris H.
    [J]. BJU INTERNATIONAL, 2010, 105 (07) : 956 - 962
  • [30] Disease insight and treatment perception of men on active surveillance for early prostate cancer
    van den Bergh, Roderick C. N.
    van Vugt, Heidi A.
    Korfage, Ida J.
    Steyerberg, Ewout W.
    Roobol, Monique J.
    Schroder, Fritz H.
    Essink-Bot, Marie-Louise
    [J]. BJU INTERNATIONAL, 2010, 105 (03) : 322 - 328